1. Home
  2. NTRA vs TRI Comparison

NTRA vs TRI Comparison

Compare NTRA & TRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$325.66

Market Cap

47.0B

Sector

Health Care

ML Signal

HOLD

Logo Thomson Reuters Corp

TRI

Thomson Reuters Corp

HOLD

Current Price

$105.72

Market Cap

46.4B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
TRI
Founded
2003
1851
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0B
46.4B
IPO Year
2015
2002

Fundamental Metrics

Financial Performance
Metric
NTRA
TRI
Price
$325.66
$105.72
Analyst Decision
Strong Buy
Buy
Analyst Count
15
12
Target Price
$259.07
$154.58
AVG Volume (30 Days)
1.3M
1.5M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
2.62%
EPS Growth
0.65
N/A
EPS
N/A
N/A
Revenue
$210,939,000.00
N/A
Revenue This Year
$18.08
$8.90
Revenue Next Year
$19.65
$7.89
P/E Ratio
N/A
$25.72
Revenue Growth
N/A
N/A
52 Week Low
$157.43
$76.28
52 Week High
$343.18
$173.39

Technical Indicators

Market Signals
Indicator
NTRA
TRI
Relative Strength Index (RSI) 60.52 61.08
Support Level $187.64 $79.70
Resistance Level $326.03 $112.09
Average True Range (ATR) 10.69 3.56
MACD -2.34 -0.03
Stochastic Oscillator 48.27 84.66

Price Performance

Historical Comparison
NTRA
TRI

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About TRI Thomson Reuters Corp

Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.

Share on Social Networks: